Literature DB >> 32011085

Effects of a selective androgen receptor modulator (SARM), GSK2849466A, on stress urinary incontinence and bladder activity in rats with ovariectomy-induced oestrogen deficiency.

Katsumi Kadekawa1, Naoki Kawamorita1, Takahiro Shimizu1, Masahiro Kurobe1, Philip S Turnbull2, Sundeep Chandra2, Takahito Kambara3, Joanna C Barton2, Alan J Russell2, Naoki Yoshimura1.   

Abstract

OBJECTIVES: To report the effect of a selective androgen receptor modulators (SARMs) on the urethral continence mechanisms in a rat model of stress urinary incontinence (SUI) induced by bilateral ovariectomy (OVX).
MATERIALS AND METHODS: Female Sprague-Dawley rats with bilateral OVX were used. Rats were divided into five groups; sham operated, vehicle-treated OVX, low-dose SARM-treated OVX (GSK2849466A: 0.005 mg/kg/day, per os [p.o.]), high-dose SARM-treated OVX (GSK2849466A: 0.03 mg/kg/day, p.o.) and dihydrotestosterone (DHT)-treated OVX (1 mg/kg/day, subcutaneous) groups. After 4 weeks of SARM treatments or 3 weeks of DHT treatment (6 weeks after OVX), rats were subjected to evaluation of the sneeze-induced continence reflex using microtransducer-tipped catheter methods, sneeze-induced leak-point pressure, and continuous cystometry measurements, followed by histological analyses of urethral tissues.
RESULTS: (i) OVX significantly impaired urethral continence function after 6 weeks to induce SUI during sneezing. (ii) Low-dose SARM treatment restored urethral baseline pressure (UBP) without affecting the amplitude of urethral response during sneezing (A-URS), partially reversing OVX-induced SUI during sneezing. (iii) High-dose SARM treatment reversed decreases in both UBP and A-URS, more effectively preventing SUI during sneezing. (iv) DHT treatment only restored A-URS without affecting UBP, partially preventing OVX-induced SUI during sneezing. (v) The high-dose SARM treatment induced hypertrophy of the striated and smooth muscle around the urethra. (vi) SARM treatment did not affect bladder function in sham or OVX rats.
CONCLUSION: Treatment with SARMs could be a more effective modality for the treatment of SUI than DHT, without affecting bladder function, by enhancing smooth- and striated muscle-mediated urethral function under stress conditions such as sneezing.
© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ovariectomy; selective androgen receptor modulators; sneeze reflex; stress; urethra; urinary incontinence

Mesh:

Substances:

Year:  2020        PMID: 32011085      PMCID: PMC7261644          DOI: 10.1111/bju.15022

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  27 in total

1.  The sex hormone receptors in the bladder in childhood - I: preliminary report in male subjects.

Authors:  S Celayir; Z Ilçe; S Dervisoglu
Journal:  Eur J Pediatr Surg       Date:  2002-10       Impact factor: 2.191

Review 2.  Risks of testosterone-replacement therapy and recommendations for monitoring.

Authors:  Ernani Luis Rhoden; Abraham Morgentaler
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245

Review 3.  Recent advances in the neurophysiology of stress urinary incontinence.

Authors:  Michael B Chancellor; Hugh Perkin; Naoki Yoshimura
Journal:  Scand J Urol Nephrol       Date:  2005

4.  Nonsteroidal selective androgen receptor modulators enhance female sexual motivation.

Authors:  Amanda Jones; Dong Jin Hwang; Charles B Duke; Yali He; Anjaiah Siddam; Duane D Miller; James T Dalton
Journal:  J Pharmacol Exp Ther       Date:  2010-05-05       Impact factor: 4.030

Review 5.  Testosterone influences libido and well being in women.

Authors:  S R Davis; J Tran
Journal:  Trends Endocrinol Metab       Date:  2001 Jan-Feb       Impact factor: 12.015

6.  Effects of ovariectomy and estrogen replacement on the urethral continence reflex during sneezing in rats.

Authors:  Takeya Kitta; Donna J Haworth-Ward; Minoru Miyazato; Masashi Honda; William C de Groat; Katsuya Nonomura; David A Vorp; Naoki Yoshimura
Journal:  J Urol       Date:  2011-08-19       Impact factor: 7.450

7.  Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands.

Authors:  Azriel Schmidt; Shun-Ichi Harada; Donald B Kimmel; Chang Bai; Fang Chen; Su Jane Rutledge; Robert L Vogel; Angela Scafonas; Michael A Gentile; Pascale V Nantermet; Sheila McElwee-Witmer; Brenda Pennypacker; Patricia Masarachia; Soumya P Sahoo; Yuntae Kim; Robert S Meissner; George D Hartman; Mark E Duggan; Gideon A Rodan; Dwight A Towler; William J Ray
Journal:  J Biol Chem       Date:  2009-10-21       Impact factor: 5.157

8.  Correlation of androgen receptors, aromatase, and 5-alpha reductase in the human vagina with menopausal status.

Authors:  Jennifer R Berman; Fernando G Almeida; Julie Jolin; Shlomo Raz; Gautam Chaudhuri; Nestor F Gonzalez-Cadavid
Journal:  Fertil Steril       Date:  2003-04       Impact factor: 7.329

9.  Effect of duloxetine, a norepinephrine and serotonin reuptake inhibitor, on sneeze-induced urethral continence reflex in rats.

Authors:  Minoru Miyazato; Yasuhiro Kaiho; Izumi Kamo; Michael B Chancellor; Kimio Sugaya; William C de Groat; Naoki Yoshimura
Journal:  Am J Physiol Renal Physiol       Date:  2008-05-14

10.  Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit.

Authors:  B A Rosenzweig; P S Bolina; L Birch; C Moran; I Marcovici; G S Prins
Journal:  Neurourol Urodyn       Date:  1995       Impact factor: 2.696

View more
  2 in total

1.  Application of estrogen for the treatment of stress urinary incontinence in mice.

Authors:  Lu Li; Shasha Hong; Li Hong; Yang Li; Xiang Li; Lian Yang; Jianfeng Liu
Journal:  Arch Gynecol Obstet       Date:  2022-02-16       Impact factor: 2.344

2.  Stress urinary incontinence and the forgotten female hormones.

Authors:  Nicholas Siddle; Eboo Versi
Journal:  Int Urogynecol J       Date:  2022-04-23       Impact factor: 1.932

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.